We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PTC299

News List

PTC Therapeutics Initiates Second Stage of FITE19 Trial Evaluating PTC299 for COVID-19 americanpharmaceuticalreview
February 19, 2021
PTC Therapeutics announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19 patients.
PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19 prnasia
November 16, 2020
PTC Therapeutics, Inc., today announced the initiation of a Phase 2/3 trial called FITE19 to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
PTC Announces the Phase 2/3 Clinical Trial to Evaluate PTC299 for COVID-19 americanpharmaceuticalreview
June 29, 2020
PTC Therapeutics announced the U.S. Food and Drug Administration (FDA) has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.
PTC Begins Phase II/III Trial of PTC299 in COVID-19 contractpharma
June 18, 2020
PTC299 has a novel dual-mechanism of action that has the potential to address high viral replication and uncontrolled inflammatory response.